{"id":"arformoterol-tartrate-inhalation-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":{"setId":"ef524b4c-68d7-c464-e053-2a95a90a7f96","title":"ARFORMOTEROL TARTRATE INHALATION SOLUTION SOLUTION [RITEDOSE PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Arformoterol tartrate is the active (R,R)-enantiomer of formoterol, a selective beta-2 adrenergic receptor agonist. Upon inhalation, it binds to beta-2 receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP, which leads to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended therapeutic effect over 12 hours or longer.","oneSentence":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:35.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment"}]},"trialDetails":[{"nctId":"NCT02275481","phase":"PHASE4","title":"A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":66},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT00685841","phase":"PHASE3","title":"A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"COPD","enrollment":717},{"nctId":"NCT00846287","phase":"NA","title":"Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":16},{"nctId":"NCT01361984","phase":"PHASE4","title":"Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2011-06","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Emphysema","enrollment":20},{"nctId":"NCT00424528","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":235},{"nctId":"NCT00250679","phase":"PHASE3","title":"Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-10","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":443},{"nctId":"NCT00064402","phase":"PHASE3","title":"Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-04","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":741},{"nctId":"NCT00691405","phase":"PHASE2","title":"A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-10","conditions":"COPD","enrollment":215},{"nctId":"NCT00583947","phase":"PHASE2","title":"A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Asthma","enrollment":53},{"nctId":"NCT00571428","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33},{"nctId":"NCT00685529","phase":"PHASE2","title":"Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-04","conditions":"COPD","enrollment":24},{"nctId":"NCT00064415","phase":"PHASE3","title":"To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-06","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":799}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BRONCHITIS ACUTE"},{"count":1,"reaction":"CONDITION AGGRAVATED"}],"_approvalHistory":[{"date":"20220302","type":"ORIG","sponsor":"RITEDOSE CORP","applicationNumber":"ANDA214736"},{"date":"20250203","type":"ORIG","sponsor":"AUCTA","applicationNumber":"ANDA218380"}],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brovana","Brovana®","BROVANA","(R,R)-formoterol","(R,R-)formoterol"],"phase":"marketed","status":"active","brandName":"Arformoterol Tartrate Inhalation Solution","genericName":"Arformoterol Tartrate Inhalation Solution","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}